While few will disagree with their motives, the authors provide no roadmap for scientific societies. It may be time to learn from the successes of commercial rivals.
When journals provide academy members a VIP submission track, do their papers perform any better?
BMJ Open is marketed as high-volume journal of rejects. Did BMJ miss on marketing or is this the future of open access publishing?